Conference Presentation, Panel, Fireside Chat
The 2014 Atlanta Summit - - Race We Can't Afford to Lose: Outsmarting Superbugs
- The outlook anticipates escalating threats from microbes and diseases, with projections that nearly 50 million people will contract food-borne illnesses annually (approximately one in six people) and at least 2 million people will acquire infections from antimicrobial-resistant organisms, resulting in an estimated 23,000 to 3,000 annual deaths respectively.
- Microbial evolution is predicted to become increasingly unpredictable and rapid, leading to resistance against nearly all current antibiotics and the emergence of new strains, such as the H30 Rex E. coli variant, which has spread globally within the last decade and poses a significant mortality risk.
- Advanced Molecular Detection (AMD) is expected to revolutionize microbial analysis by reducing testing timelines from months to hours, enabling the rapid sequencing of single genomes for approximately $50 per test (down from $500,000 seven years prior) and facilitating immediate identification of infectious disease clusters.
- Implementation of AMD is presented as critical for public health efficacy, allowing the CDC to direct resource allocation effectively, render drug-resistant tuberculosis and bioterrorism challenges solvable, and replace obsolete technologies like PFGE.
- Inaction is identified as the primary risk, with warnings that without AMD adoption and global collaboration, the CDC will lack necessary tools to interface with partners, potentially leading to greater loss of life and failure to manage threats crossing political boundaries.
- Global agricultural and food processing systems are forecasted to introduce significant contamination risks due to expectations of year-round fresh produce, necessitating international cooperation through initiatives like the FDA Beyond Our Borders program to build quality at points of production in countries such as China and India.
- Financial burdens associated with infections are estimated to range from $40 billion to over $100 billion annually in the United States, driving the urgent need for prudent antibiotic use laws and public education on hygiene and appropriate medication consumption.
- Strategic partnerships are planned between the CDC, NIH, FDA, and academic institutions like George Washington University, who will serve as early adopters to validate new diagnostic technologies before deploying them for broader public health application.
- The CDC acknowledges being currently behind in technological capabilities and aims to catch up through collaborative efforts, continuous resource deployment, and 24-7 operations to protect the American public and export excellence globally.
- Specific goals include revitalizing older antibiotics like tetracyclines and ampicillins through direct DNA analysis from patient samples, thereby avoiding the 48-hour delay required for traditional culture growth and enabling the use of previously discarded drugs.